Wed, Oct 22, 2014, 12:51 AM EDT - U.S. Markets open in 8 hrs 39 mins

Recent

% | $
Quotes you view appear here for quick access.

XOMA Corporation Message Board

  • gfhammond1996 gfhammond1996 Dec 3, 2012 1:57 PM Flag

    anything here?

    Gates just mentioned Mayo.

    The commonly prescribed diabetes drug metformin could potentially double as an effective form of ovarian cancer treatment, according to a new study.
    Researchers from the Mayo Clinic found that ovarian cancer patients – who also had diabetes – lived longer than other ovarian cancer patients when they were taking metformin. According to the scientists, they had been researching the link between metformin and its potential anti-cancer properties for many years.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • gf,

      Varian said that xoma plans on collecting results for all poc's before they decide which indication to pursue, if any. clearly, xoma is following the lead of anakinra carved through the mountainous terrains in search of an indication they will work on. For example, in regards acne vulgaris:

      "The TNF-a inhibitor infliximab and anakinra are investigational drugs in these severe forms and show promising effects"

      Maybe the question is what if one or more of the poc's shows enough promise to continue? What should xoma do? Will xoma really put a promising indication on the backburner when they are so starved for revenue?
      - - - - - - - - - - - - - - - - - - - - - -
      On the 11/07/2012 audio varian estimated poc #3 would be announced in 4-6 weeks which puts the announcement between 12/5 and 12/19, so within the next 2 weeks we should find out what the mystery is.

      Did you hear in the same audio Varian mentioned aceon had sales of $150M outside the u.s.? Varian also said that it is a relatively new product which is showing good sales growth.

      Xoma should get aceon combination approval (assuming 12 months review period) by the beginning of 2014. Xoma has enough cash to get through 2014. Xoma should muster more cash [than present aceon figures) all through 2014.

      In the same audio, Varian estimates tests of xmeta, and xmets should be complete with higher animals in 12-18 months which puts us at the latest of mid 2014. xmetd should also be ready for beginning trials by mid 2014. Hopefully, xoma can auction license/development agreements before the end of 2014.

    • gf,
      I tried to post this before to another question about diabetes type 1 POC3, so i'll try here:

      No, I don't think so because the purpose of all the POC's are relatively short term and easy to measure. varian has stated that xoma plans on collecting results for ALL POC's before they decide which indication to pursue, if any. Clearly, xoma is following the lead anakinra carved through the mountainous terrains in search of an indication they will work on. For example in regards acne vulgaris:

      "TheTNF-α inhibitor infliximab and anakinra are investigational drugs in these severe forms and show promising effects"
      [Do a search on the above. Look at the box with pictures in it at the top, the fellow with the blue shirt and white collar. That is some severe acne.]
      ------------------------------------------------------------------------
      11/7/2012 audio varian estimated POC #3 announced in 4-6 weeks which puts the announcement at 12/5 to 12/19/2012.

      did you hear in the 11/7/2012 xoma audio varian mentions aceon had sales of $150M outside the u.s.? Is this the servier version he is talking about. varian also said that the it is a relatively new product which is showing sales growth as time goes on.

      xoma should get NDA review for aceon combinations by the beginning of 2014. xoma has enough cash to get through 2014. If xoma could muster 10M+ through 2014 in aceon it would be significant help. In the same 11/7 audio, varian estimates tests of xmeta, and xmets should be complete with primates in 12-18 months which puts us at the latest mid 2014. xmetd should be ready for trials by mid 2014 also. Hopefully, xoma can auction off license/development agreements before the end of 2014 with some up front money too. at the very least it will indicate a promising drug.

      Maybe the question is what if? What if one or more of the poc's shows enough promise to continue? What should xoma do? How would xoma get through a phase 3 POC trial?

 
XOMA
4.27+0.02(+0.47%)Oct 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.